Impact of NK1 Antagonists on Chemotherapy-Induced Neutropenia in Lung Cancer Patients

99 patients with non-small cell lung cancer treated between January 2019 and September 2024 were analyzed in this retrospective study by Kenta Yamaoka. It compares the incidence of grade ≥3 neutropenia in patients receiving antiemetics fosnetupitant versus aprepitant alongside paclitaxel-based chemotherapy. The data suggests a significantly higher incidence of neutropenia with fosnetupitant in paclitaxel-treated patients.

Use Cases

• Compare adverse event rates between different antiemetic regimens based on the reported incidence of grade ≥3 neutropenia.
• Investigate the interaction between NK1 receptor antagonists and CYP3A4-metabolized drugs based on the described pharmacology.
• Assess risk factors for chemotherapy-induced myelosuppression based on the patient cohort and treatment groups described.
• Support pharmacovigilance studies for novel antiemetic agents like fosnetupitant based on the comparative safety analysis.

Strengths

• Includes specific patient counts and statistical results (e.g., 15/31 vs. 18/68 incidence rates with p=0.019).
• Focuses on a clinically relevant endpoint (grade ≥3 neutropenia) with a defined study period (2019-2024).
• Uses a comparative study design with two distinct patient groups (fosnetupitant vs. aprepitant).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (22.8 KB), indicating limited scope and sample size.

Provenance

Source

figshare

Collection Method

Retrospective study of patient records.

Time Range

January 2019 to September 2024

Freshness

Last updated 2026-05-11 05:28:54; freshness should be verified.